Heterogeneity of autoantibodies against cardiolipin and oxidatively modified LDLs revealed by human monoclonal antibodies.
Human monoclonal antibodies against cardiolipin, native and oxidatively modified LDL and against apoB100 were obtained by Epstein-Barr virus transformation of peripheral blood mononuclear cells followed by cloning. The antibodies were used to analyse the cross-reactivity between monoclonals with different specificities and to study the repertoire of antibodies present in sera from patients. Monoclonal antibodies selected for binding to cardiolipin were the least cross-reactive, whereas antibodies against different modifications of LDL frequently also reacted with other modifications. Inhibition studies showed that serum antibodies against cardiolipin and against oxidatively modified LDL were to a different extent inhibited by the different monoclonal antibodies and thus markedly heterogeneous.